Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02495896
Recruitment Status : Recruiting
First Posted : July 13, 2015
Last Update Posted : August 13, 2018
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Vasgene Therapeutics, Inc
Information provided by (Responsible Party):
University of Southern California

Brief Summary:
This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard chemotherapy regimens in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have spread to other places in the body (metastatic). Drugs used in chemotherapy, such as recombinant EphB4-HSA fusion protein, paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, docetaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether standard chemotherapy regimens are more effective with recombinant ephB4-HSA fusion protein in treating advanced or metastatic solid tumors.

Condition or disease Intervention/treatment Phase
Head and Neck Squamous Cell Carcinoma Metastatic Pancreatic Adenocarcinoma Non-Resectable Cholangiocarcinoma Pancreatic Adenocarcinoma Recurrent Gallbladder Carcinoma Recurrent Non-Small Cell Lung Carcinoma Stage III Pancreatic Cancer Stage IIIA Gallbladder Cancer Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Gallbladder Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Gallbladder Cancer Stage IV Non-Small Cell Lung Cancer Stage IV Pancreatic Cancer Unresectable Gallbladder Carcinoma Unresectable Pancreatic Cancer Drug: Cisplatin Drug: Docetaxel Drug: Gemcitabine Hydrochloride Other: Laboratory Biomarker Analysis Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation Other: Pharmacological Study Biological: Recombinant EphB4-HSA Fusion Protein Phase 1

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Multi-arm Study of sEphB4-HSA in Combination With Different Chemotherapy Regimens in Patients With Specific Advanced or Metastatic Solid Tumors
Study Start Date : September 3, 2015
Estimated Primary Completion Date : September 3, 2019
Estimated Study Completion Date : December 3, 2020


Arm Intervention/treatment
Experimental: Arm A (sEphB4-HSA, nab-paclitaxel, gemcitabine hydrochloride)
Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22 (beginning course 2), paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Gemcitabine Hydrochloride
Given IV
Other Names:
  • dFdCyd
  • Difluorodeoxycytidine Hydrochloride
  • Gemzar
  • LY-188011

Other: Laboratory Biomarker Analysis
Correlative studies

Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Given IV
Other Names:
  • ABI 007
  • ABI-007
  • Abraxane
  • Albumin-bound Paclitaxel
  • Albumin-Stabilized Nanoparticle Paclitaxel
  • nab-paclitaxel
  • Nanoparticle Albumin-bound Paclitaxel
  • Nanoparticle Paclitaxel
  • protein-bound paclitaxel

Other: Pharmacological Study
Correlative studies

Biological: Recombinant EphB4-HSA Fusion Protein
Given IV
Other Name: sEphB4-HSA

Experimental: Arm B (sEphB4-HSA, docetaxel)
Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2) and docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Drug: Docetaxel
Given IV
Other Names:
  • RP56976
  • Taxotere
  • Taxotere Injection Concentrate

Other: Laboratory Biomarker Analysis
Correlative studies

Other: Pharmacological Study
Correlative studies

Biological: Recombinant EphB4-HSA Fusion Protein
Given IV
Other Name: sEphB4-HSA

Experimental: Arm C (sEphB4-HSA, cisplatin, gemcitabine hydrochloride)
Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2), cisplatin IV over 120 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Drug: Cisplatin
Given IV
Other Names:
  • Abiplatin
  • Blastolem
  • Briplatin
  • CDDP
  • Cis-diammine-dichloroplatinum
  • Cis-diamminedichloridoplatinum
  • Cis-diamminedichloro Platinum (II)
  • Cis-diamminedichloroplatinum
  • Cis-dichloroammine Platinum (II)
  • Cis-platinous Diamine Dichloride
  • Cis-platinum
  • Cis-platinum II
  • Cis-platinum II Diamine Dichloride
  • Cismaplat
  • Cisplatina
  • Cisplatinum
  • Cisplatyl
  • Citoplatino
  • Citosin
  • Cysplatyna
  • DDP
  • Lederplatin
  • Metaplatin
  • Neoplatin
  • Peyrone's Chloride
  • Peyrone's Salt
  • Placis
  • Plastistil
  • Platamine
  • Platiblastin
  • Platiblastin-S
  • Platinex
  • Platinol
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Platinum
  • Platinum Diamminodichloride
  • Platiran
  • Platistin
  • Platosin

Drug: Gemcitabine Hydrochloride
Given IV
Other Names:
  • dFdCyd
  • Difluorodeoxycytidine Hydrochloride
  • Gemzar
  • LY-188011

Other: Laboratory Biomarker Analysis
Correlative studies

Other: Pharmacological Study
Correlative studies

Biological: Recombinant EphB4-HSA Fusion Protein
Given IV
Other Name: sEphB4-HSA




Primary Outcome Measures :
  1. Duration of overall response or SD [ Time Frame: From first occurrence of CR, PR or SD to the time of documented disease progression, as determined by investigator review of tumor assessments using RECIST v1.1, or death from any cause, assessed up to 2 years ]
  2. Incidence of toxicities, graded according to Common Terminology Criteria for Adverse Events version 4 [ Time Frame: Up to 2 years ]
  3. Objective response using RECIST version 1.1 [ Time Frame: Up to 2 years ]
    Patients whose best overall response is CR or PR will be classified as having a major objective response.

  4. Overall survival [ Time Frame: Time from start of treatment with recombinant EphB4-HSA fusion protein (start of 2nd course) to death for any cause, assessed up to 2 years ]
  5. Progression-free survival [ Time Frame: Time from start of treatment to 1st documentation of PD or death due to any cause, or death from any cause, assessed up to 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
  • Patients must have a life expectancy of at least 12 weeks
  • Patients must be able to comprehend and provide written informed consent
  • Women of childbearing potential (WOCBP) and male patients with WOCBP partner must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of investigational product in such a manner that the risk of pregnancy is minimized; WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal; post menopause is defined as:

    • Amenorrhea >= 12 consecutive months without another cause or
    • For women with irregular menstrual periods and on hormone replacement therapy (HRT), a documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL
    • Women who are using oral contraceptives, other hormonal contraceptives (vagina products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (e.g., vasectomy) should be considered to be of childbearing potential
  • WOCBP must have a negative serum test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 72 hours prior to the start of investigational product
  • Patients with hepatitis B infection must be on appropriate antiviral therapy
  • ARM A COHORT 1: Patients must have advanced pancreatic adenocarcinoma (unresectable or metastatic)
  • ARM A COHORT 1: Patients must not have received prior therapy for metastatic or advanced disease; adjuvant therapy that is gemcitabine based is allowed as long as the adjuvant treatment was completed >= 6 months before the diagnosis of recurrent disease
  • ARM A COHORT 1: Absolute neutrophil count >= 1,500/ul
  • ARM A COHORT 1: Platelet count >= 100,000/ul
  • ARM A COHORT 1: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN); if liver metastases are present then must be < 5 X the ULN
  • ARM A COHORT 1: Total bilirubin =< 1.5 x ULN
  • ARM A COHORT 1: Creatinine =< 1.5 x institutional ULN, or creatinine clearance >= 50 mL/min (calculated with the Cockcroft-Gault formula)
  • ARM A COHORT 1: Serum albumin >= 2.5 g/dL
  • ARM B COHORT 2: Patients must have a histologically confirmed diagnosis of head and neck (squamous cell) carcinoma
  • ARM B COHORT 2: Patients must have failed treatment with platinum based therapy with or without cetuximab; previous therapy with a platinum concurrent with radiation followed by progression of disease within 6 months will count as failure of one prior line of cisplatin based therapy
  • ARM B COHORT 2: Absolute neutrophil count >= 1,500/ul
  • ARM B COHORT 2: Platelet count >= 100,000/ul
  • ARM B COHORT 2: AST and ALT =< 2 X ULN; if liver metastases are present then must be < 5 X the ULN
  • ARM B COHORT 2: Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)
  • ARM B COHORT 2: Serum albumin >= 2.5 g/dL
  • ARM B COHORT 2: Creatinine =< 1.5 x institutional ULN, or creatinine clearance >= 50 mL/min (calculated with the Cockcroft-Gault formula)
  • ARM B COHORT 3: Patients must have a histologically confirmed diagnosis of non-small cell lung cancer
  • ARM B COHORT 3: Patients must have failed one prior line of systemic therapy for the treatment of advanced non-small cell lung cancer; prior adjuvant therapy with subsequent recurrence within 6 months of completion of therapy will count as one prior line of systemic therapy and such patients will be eligible
  • ARM B COHORT 3: Absolute neutrophil count >= 1,500/ul
  • ARM B COHORT 3: Platelet count >= 100,000/ul
  • ARM B COHORT 3: AST and ALT =< 2 X ULN; if liver metastases are present then must be < 5 X the ULN
  • ARM B COHORT 3: Total bilirubin =< 1.5 x IULN
  • ARM B COHORT 3: Serum albumin >= 2.5 g/dL
  • ARM B COHORT 3: Creatinine =< 1.5 x institutional ULN, or creatinine clearance >= 50 mL/min (calculated with the Cockcroft-Gault formula)
  • ARM C COHORT 4: Patients must have a histologically or cytologically proven diagnosis of advanced (unresectable or metastatic) gallbladder cancer or cholangiocarcinoma and be candidates for first line therapy with gemcitabine and cisplatin
  • ARM C COHORT 4: Patients must not have received prior systemic chemotherapy for advanced or metastatic disease; prior adjuvant chemotherapy or concurrent chemotherapy and radiation are allowed if they were completed >= 6 months prior to the diagnosis of recurrent disease
  • ARM C COHORT 4: Absolute neutrophil count >= 1,500/ul
  • ARM C COHORT 4: Platelet count >= 100,000/ul
  • ARM C COHORT 4: AST and ALT =< 5 x ULN
  • ARM C COHORT 4: Total bilirubin =< 2 X IULN
  • ARM C COHORT 4: Serum albumin >= 2.5 g/dL
  • ARM C COHORT 4: Creatinine =< 1.5 x institutional ULN, or creatinine clearance >= 50 mL/min (calculated with the Cockcroft-Gault formula)
  • ARM C COHORT 4: Patients who have had decompression of the biliary tree within the last 14 days, must have a stable bilirubin level as confirmed by two measurements that are within 5 to 7 days of each other; (the second measurement must be obtained within 7 days prior to registration); both the first and second measurement must be =< 2 X IULN; stability is defined as the second measurement being no more than one point higher than the first

Exclusion Criteria:

  • Patients must not have received any anti-cancer therapy (cytotoxic chemotherapy, targeted therapy or radiation) within the past 28 days prior to initiation of study therapy
  • Patients must not have an active major systemic infection requiring systemic antibiotics 72 hours or less prior to the first dose of study drug
  • Patients must not have untreated central nervous system (CNS) metastases; patients whose CNS metastases have been treated by surgery or radiotherapy, who are no longer on corticosteroids, and who are neurologically stable may be enrolled
  • Patients must not have any of the following: New York Heart Association (NYHA) class 3 or 4 congestive heart failure; myocardial infarction within the past 12 months, acute coronary syndrome, diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding 6 months; or any other intercurrent medical condition that contra-indicates treatment with sEphB4HSA or places the patient at undue risk for treatment related complications
  • Patients must not have any other condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results
  • Patients must not be pregnant of lactating
  • Patients must not be on any dose of warfarin or are on full dose anticoagulation with other agents, including low molecular weight heparin, antithrombin agents, anti-platelet agents and full dose aspirin within 7 days prior to first dose of study drug; patients on prophylactic doses of low-molecular weight heparin are allowed
  • Patients must not have had any active bleeding in the last =< 4 weeks or have an otherwise known bleeding diathesis
  • Patients must not have corrected QT (QTc)F (Fridericia Correction Formula) > 480 on 2 out of 3 electrocardiograms (EKG's) (if first EKG is =< 480, no need to repeat, if first EKG is > 480 repeat twice for a total of 3 EKG's)
  • Patients must not have uncontrolled hypertension as defined by systolic blood pressure (SBP) >= 160 mmHg or diastolic blood pressure (DBP) >= 90 mmHg; patients whose blood pressure can be controlled medically are allowed to be rescreened once blood pressure (BP) is under control
  • Patients must not have > grade sensory neuropathy
  • Patients must not have known human immunodeficiency virus (HIV) infection
  • ARM A COHORT 1: Patients must not have prior nab-paclitaxel exposure
  • ARM A COHORT 1: Patients must not have a history of slowly progressive dyspnea and unproductive cough, or of conditions such as sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, or multiple allergies
  • ARM B COHORT 2: Patients must not have prior exposure to docetaxel
  • ARM B COHORT 2: Patients with head and neck cancer must not have radiologic evidence of major arterial involvement
  • ARM B COHORT 3: Patients must not have prior exposure to docetaxel
  • ARM B COHORT 3: Patients must not have had more than one prior line of systemic therapy for advanced non-small cell lung cancer (including treatment with a targeted agent); prior adjuvant therapy completed more than 6 months prior to disease recurrence will not count as a prior line of systemic therapy for advanced disease
  • ARM B COHORT 3: Patients must not have active clinically significant hemoptysis
  • ARM B COHORT 3: Patients must not have a central lesion with radiologic evidence of arterial involvement
  • ARM C COHORT 4: Patients must not have prior cisplatin exposure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02495896


Contacts
Layout table for location contacts
Contact: Xiomara Menendez, RN 323-409-4368 Xiomara.Menendez@med.usc.edu
Contact: Jessica Levano, RN 323-865-0593 levano_j@med.usc.edu

Locations
Layout table for location information
United States, California
USC / Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: Anthony El-Khoueiry    323-865-3967    elkhouei@usc.edu   
Principal Investigator: Anthony El-Khoueiry, MD         
Hoag Memorial Hospital Presbyterian Recruiting
Newport Beach, California, United States, 92663
Contact: Alicia Bogardus, MA    949-764-6755    Alicia.bogardus@hoag.org   
Contact: Cristina De Leon, RN    949-764-5543    Cristina.deleon@hoag.org   
Sub-Investigator: Diana Hanna, MD         
Sponsors and Collaborators
University of Southern California
National Cancer Institute (NCI)
Vasgene Therapeutics, Inc
Investigators
Layout table for investigator information
Principal Investigator: Anthony El-Khoueiry University of Southern California

Layout table for additonal information
Responsible Party: University of Southern California
ClinicalTrials.gov Identifier: NCT02495896     History of Changes
Other Study ID Numbers: 0S-15-5
NCI-2015-00987 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
0S-15-5 ( Other Identifier: USC / Norris Comprehensive Cancer Center )
P30CA014089 ( U.S. NIH Grant/Contract )
First Posted: July 13, 2015    Key Record Dates
Last Update Posted: August 13, 2018
Last Verified: August 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Adenocarcinoma
Pancreatic Neoplasms
Cholangiocarcinoma
Squamous Cell Carcinoma of Head and Neck
Gallbladder Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Carcinoma, Squamous Cell
Digestive System Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Head and Neck Neoplasms
Biliary Tract Neoplasms
Biliary Tract Diseases
Gallbladder Diseases
Gemcitabine
Paclitaxel